As Biotechnology businesses, FibroGen Inc. (NASDAQ:FGEN) and Sutro Biopharma Inc. (NASDAQ:STRO), are affected by compare. This especially applies to their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sutro Biopharma Inc.||23.37M||11.13||49.17M||-2.21||0.00|
Table 1 demonstrates FibroGen Inc. and Sutro Biopharma Inc.’s top-line revenue, earnings per share and valuation.
Table 2 demonstrates the return on equity, return on assets and net margins of FibroGen Inc. and Sutro Biopharma Inc.
|Net Margins||Return on Equity||Return on Assets|
|Sutro Biopharma Inc.||-210.40%||0%||0%|
6.8 and 6.8 are the respective Current Ratio and a Quick Ratio of FibroGen Inc. Its rival Sutro Biopharma Inc.’s Current and Quick Ratios are 3.5 and 3.5 respectively. FibroGen Inc. has a better chance of clearing its pay short and long-term debts than Sutro Biopharma Inc.
The table delivered features the ratings and recommendations for FibroGen Inc. and Sutro Biopharma Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Sutro Biopharma Inc.||0||0||0||0.00|
FibroGen Inc.’s upside potential is 37.99% at a $75 consensus price target.
Insider & Institutional Ownership
Roughly 67.3% of FibroGen Inc. shares are owned by institutional investors while 75.3% of Sutro Biopharma Inc. are owned by institutional investors. 4.3% are FibroGen Inc.’s share owned by insiders. Insiders Comparatively, owned 8.5% of Sutro Biopharma Inc. shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Sutro Biopharma Inc.||-9.77%||-14.46%||-12.05%||0%||0%||0.33%|
For the past year FibroGen Inc.’s stock price has bigger growth than Sutro Biopharma Inc.
FibroGen Inc. beats Sutro Biopharma Inc. on 8 of the 11 factors.
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.